Rani Therapeutics Announces New Preclinical Data Supporting Transenteric Delivery Of GLP-1 Incretin Triagonist With Rapid Weight Loss And Bioavailability Comparable To Injection
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics has released new preclinical data showing that their RaniPill platform can deliver a GLP-1 incretin triagonist orally, achieving rapid weight loss and bioavailability similar to injections. A Phase 1 study for RT-114 is expected in 2025.
October 17, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics' new preclinical data suggests their RaniPill platform can effectively deliver GLP-1 incretin triagonist orally, with results comparable to injections. This innovation could significantly impact obesity treatment markets.
The announcement of successful preclinical data for the RaniPill platform indicates a potential breakthrough in oral obesity treatments, which could enhance Rani Therapeutics' market position. The anticipation of a Phase 1 study in 2025 further supports positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100